Background {#Sec1}
==========

The development of new anti-cancer drugs and imaging techniques, such as low-dose computed tomography (CT), has improved the survival rate in patients with primary pulmonary malignancy \[[@CR1]--[@CR3]\]. However, lung cancer is still one of the most fatal malignancies, and many patients die of complications related to disease progression \[[@CR4], [@CR5]\]. In particular, central airway obstruction is one of the major complications and causes hemoptysis, atelectasis, and obstructive pneumonia. Eventually, these patients experience disability in daily activities and are at increased risk of repeated hospitalization for respiratory failure \[[@CR6]\].

Malignant central airway obstruction (MCAO), which is defined as ≥50% occlusion of the cross-sectional area of the central airway, occurs in 20--30% of patients with primary pulmonary malignancy caused by endoluminal metastasis or extrinsic compression of bulky lymphadenopathy \[[@CR7]\]. In patients with MCAO, surgical interventions are rarely indicated for tumors obstructing the trachea and main carina \[[@CR8]\]. The effects of chemotherapy or radiation therapy may take a long time to relieve the MCAO \[[@CR9]\]. However, bronchoscopic interventions, such as mechanical debulking, laser cauterization, and stent placement, can immediately relieve symptoms related to airway obstruction and improve quality of life \[[@CR10]\]. Previous studies have demonstrated the efficacy of this procedure in decreasing the frequency and severity of dyspnea and improving other clinically relevant endpoints \[[@CR8], [@CR11]--[@CR13]\]. In multicenter studies, more than 90% success rates and low complication rates have been confirmed following interventional bronchoscopy in patients with MCAO \[[@CR14]\]. However, to the best of our knowledge, few articles have reported the prognostic factors associated with survival after bronchoscopic intervention.

Therefore, the purpose of our study was to evaluate the clinical outcomes and prognostic factors of bronchoscopic interventions in patients with MCAO due to primary pulmonary malignancy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The characteristics of airway obstruction were assessed by CT and, when possible, flexible bronchoscopy. MCAO was defined as ≥50% occlusion of the cross-sectional area of the central airway (from trachea to lobar bronchus) on CT or bronchoscopic findings \[[@CR14]\]. From January 2004 to December 2017, interventional bronchoscopy was performed in 295 patients with MCAO due to primary pulmonary malignancy at Samsung Medical Center, a university-affiliated hospital in South Korea. Patients with salivary gland-type tumors (*n* = 71), such as adenoid cystic carcinoma, mucoepidermoid carcinoma, and epithelial-myoepithelial carcinoma, were excluded from this study because of their biological differences and good prognosis due to being distinguished from non-small cell and small cell lung cancer \[[@CR15]--[@CR18]\]. Finally, total 224 patients were analyzed.

The Institutional Review Board of Samsung Medical Center approved this study (2019--03-002) and waived informed consent due to its retrospective nature.

Airway interventional techniques {#Sec4}
--------------------------------

Interventional bronchoscopy was performed according to standard techniques \[[@CR19], [@CR20]\]. Details of airway interventional techniques were described in previous reports \[[@CR21]\]. In short, after induction of general anesthesia and intubation with a rigid bronchoscope tube (Bryan Co., Woburn, MA, USA or Karl-Storz, Tuttlingen, Germany), various combinations of airway intervention techniques (mechanical debulking, laser, and insertion of silicone stents) were used depending on the characteristics of airway obstruction. Any intraluminal mass was removed mechanically using rigid bronchoscope tubes and cauterized by using neodymium-doped yttrium aluminum garnet laser (LaserSonics, Milpitas, CA, USA) or diode laser (Biolitec, Ceralas®, Germany). Additionally, if there was an extrinsic compression or high likelihood of rapid tumor ingrowth, a silicone stent (Natural stent \[M1S Co., Seoul, Korea\] or Dumon stent \[Novatech, La Ciotat, France\]) was inserted to maintain airway patency \[[@CR21]\].

Technical success was assessed based on the anatomic criteria of reopening of the airway lumen to \> 50% of the normal cross-sectional area and connection to a viable area in the distal lung on bronchoscopy \[[@CR14]\]. If a physician successfully reopened a proximal airway but discovered distal lesions occluding all segmental or subsegmental levels, we classified this as a technical failure \[[@CR14]\].

Data collection {#Sec5}
---------------

We retrospectively analyzed the medical data from 224 patients using the following data: demographic characteristics, histological type of malignancy, bronchoscopic findings (site of lesion, type of obstruction, and severity and length of stenosis), pre- and post-procedure treatment modalities, airway intervention techniques, procedure-related complications, and survival period.

The following terms were defined identically to our previous report \[[@CR21]\]. Poor performance was defined as ≥ American Society of Anesthesiologists (ASA) physical status class 3, which means severe systemic disease with functional limitations \[[@CR22]\]. We evaluated the severity of airway stenosis using the Myer-Cotton stenosis grading system: Grade I, ≤50% luminal stenosis; Grade II, 51--70% luminal stenosis; Grade III, 71--99% luminal stenosis; Grade IV, no lumen \[[@CR23]\]. Respiratory distress was defined as decrease in oxygen saturation or worsened dyspnea after the procedure and need for additional oxygen for at least 24 h \[[@CR21]\]. We defined excessive bleeding as procedure-related bleeding in which blood transfusion or escalated care was needed \[[@CR21]\]. Because most patients with MCAO due to primary pulmonary malignancy were already far advanced at the time of the first bronchoscopic intervention, the status of malignancy was defined as follows \[[@CR21]\]. The first category was when the MCAO was discovered along with the initial diagnosis of primary pulmonary malignancy that had never been treated, and the second one was when the MCAO was caused by progression of a primary pulmonary malignancy that had already been treated with anti-cancer treatment. Finally, we investigated whether the patients had received any adjuvant therapy after the bronchoscopic intervention.

Statistical analysis {#Sec6}
--------------------

Data are presented as number (%) for categorical variables and median (interquartile range \[IQR\]) for continuous variables. The Kaplan-Meier method was used to estimate the overall survival rate after the first bronchoscopic intervention. A multivariable Cox proportional hazard regression analysis with backward stepwise selection, with *P* \<  0.05 for entry of variables, and *P* \> 0.10 for removal of variables were used to identify independent prognostic factors associated with overall survival. Statistical differences were considered significant at *P* \<  0.05. All statistical analyses were performed using SPSS software (IBM SPSS Statistics ver. 25, Chicago, IL, USA).

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

The characteristics of the study population are described in Table [1](#Tab1){ref-type="table"}. Among 224 patients, 191 (85.3%) were male, and the median age was 63 (IQR, 56--69) years. Of these patients, 176 (78.6%) had a smoking history of median 40 (IQR, 30--50) pack-year. The most common comorbidity was chronic pulmonary disease (20.1%). Sixty-eight patients (30.4%) had a poor performance status, and intubation was required before the intervention in 27 (12.1%) patients. Squamous cell carcinoma (71.0%) was the most common histological type of malignancy. Table 1Baseline characteristicsVariables*N* = 224Age, years63 (56--69)Sex, male191 (85.3)Body mass index, kg/m^2^21.9 (20.1--24.1)Smoking Never smoker48 (21.4) Ex-smoker102 (45.5) Current smoker74 (33.0) Pack-year (*n* = 166)^a^40 (30--50)Comorbidity Chronic pulmonary disease45 (20.1) Diabetes mellitus31 (13.8) Congestive heart disease15 (6.7) Chronic liver disease10 (4.5) Chronic kidney disease5 (2.2) Cerebrovascular disease2 (0.9)Poor performance status^b^68 (30.4)Intubation due to respiratory failure before intervention27 (12.1)Histological type of malignancy Non-small cell carcinoma215 (96.0)  Squamous cell carcinoma159 (71.0)  Adenocarcinoma40 (17.9)  Others^c^16 (7.1)Small cell carcinoma9 (4.0)Data are presented as *n* (%) or the median (interquartile range)^a^ Excluding never smoker and 11 patients with ex-smoker who had no information^b^ American Society of Anesthesiologists (ASA) physical status class ≥3 means severe systemic disease with functional limitation^c^ Poorly differentiated (*n* = 7), large cell neuroendocrine carcinoma (*n* = 3), pleomorphic carcinoma (*n* = 3), lymphoepithelioma-like carcinoma (*n* = 1), sarcomatoid carcinoma (*n* = 1), basaloid squamous cell carcinoma (*n* = 1)

Characteristics of the MCAO site are described in Table [2](#Tab2){ref-type="table"}. Among 224 patients, 173 (77.2%) had a single-site obstruction, while 51 (22.8%) had obstructions at two or more sites. Endobronchial, mixed, and extrinsic types of obstructions were identified in 125 (55.8%), 80 (35.7%), and 19 (8.5%) patients, respectively. Most patients (76.8%) had ≥71% obstruction of the cross-sectional area (Myer and Cotton Grade III or IV). The median length of stenosis was 27 mm (IQR, 18--35 mm). Some patients (2.2%) had a fistula between the trachea and esophagus. Table 2Bronchoscopic findingsVariables*N* = 224Site of lesion Single lesion173 (77.2)  Trachea44 (19.6)  Left main bronchus45 (20.1)  Right main bronchus37 (16.5)  Right bronchus intermedius20 (8.9)  Lobar bronchus27 (12.1) Extended lesion51 (22.8)  Trachea and each or both bronchi26 (11.6)  Both bronchi25 (11.2)Type of obstruction Endobronchial lesion125 (55.8) Extrinsic compression19 (8.5) Mixed lesion80 (35.7)Severity of stenosis (Myer and Cotton grade)^a^ II52 (23.1) III97 (43.4) IV75 (33.5)Length of MCAO^b^, mm27 (18--35)Combined fistula from trachea to esophagus5 (2.2)Data are presented as *n* (%) or the median (interquartile range)*MCAO* malignant central airway obstruction^a^Categorization based on the percentage of reduction in cross-sectional area. Grade 1, ≤ 50% lumenal stenosis; Grade II, 51--70% lumenal stenosis; Grade III, 71--99% lumenal stenosis; Grade IV, no lumen^b^Length of MCAO was defined as the sum of the length of the obstructive lesions more than grade II

Treatment modalities and complications {#Sec9}
--------------------------------------

Treatment-related information is detailed in Table [3](#Tab3){ref-type="table"}. There was an average of 0.5 months (IQR, 0.2--1.3 months) from diagnosis of MCAO to the first bronchoscopic intervention. The median procedure time was 35 min (IQR, 28--45 min). Mechanical debulking was performed in patients who had endobronchial and mixed lesions; additional procedures, such as stent insertion (50.4%), laser cauterization (31.7%), and ballooning (10.3%), were used in combination according to the characteristics of the individual lesions. During the study period, 55 (24.6%) patients received two or more bronchoscopic interventions. Overall, technical success was achieved in 93.7%. Of the 96 (42.9%) patients who were diagnosed with MCAO during initial diagnosis of malignancy, 27 (12.1%) did not receive adjuvant treatment after interventional bronchoscopy because of poor general condition (*n* = 23) or rejection of additional treatment by the patient (*n* = 4). Of 128 (57.1%) patients diagnosed with MCAO as a part of the disease progression of malignancy, 42 (18.7%) did not receive adjuvant treatment after interventional bronchoscopy due to of poor general condition (*n* = 32), rejection of additional treatment (*n* = 7), or lack of further treatment options (*n* = 3). Table 3Treatment modalities and complicationsVariables*N* = 224Time interval from diagnosis of MCAO to treatment, months0.5 (0.2--1.3)Procedure time, min35 (28--45)Treatment modalities Mechanical debulking205 (91.5) Silicone stent113 (50.4)  Tube stent96 (42.9)  Y stent17 (7.6) Laser71 (31.7) Ballooning23 (10.3)Number of interventional bronchoscopies 1169 (75.4)  ≥ 255 (24.6)Technical failure14 (6.3)MCAO as initial diagnosis of malignancy96 (42.9) No adjuvant treatment after interventional bronchoscopy27 (12.1) Adjuvant radiation therapy44 (19.6) Adjuvant chemotherapy31 (13.8) Adjuvant surgical resection19 (8.5)MCAO as disease progression of malignancy128 (57.1) No adjuvant treatment after interventional bronchoscopy42 (18.8) Adjuvant radiation therapy49 (21.9) Adjuvant chemotherapy56 (25.0) Adjuvant surgical resection6 (2.7)Acute complications33 (17.0) Respiratory distress18 (8.0) Excessive bleeding14 (6.3) Pneumothorax3 (1.3) Procedure-related death^a^3 (1.3)Chronic complications48 (21.4) Granulation tissue overgrowth26 (11.6) Restenosis20 (8.9) Mucostasis16 (7.1) Stent migration3 (1.3)Data are presented as *n* (%) or the median (interquartile range)*MCAO* malignant central airway obstructionPatients could undergo more than one adjuvant treatmentPatients could have one more complications^a^ Three patients died of excessive bleeding (*n* = 2) and tension pneumothorax (*n* = 1)

Acute complications occurred in 33 (17%) patients, comprising excessive bleeding (*n* = 14), respiratory distress (*n* = 18), and pneumothorax (*n* = 3). Three procedure-related deaths were recorded due to excessive bleeding (*n* = 2) and tension pneumothorax (*n* = 1). Although chronic complications occurred in 48 (21.4%) patients, including granulation tissue overgrowth (*n* = 26), restenosis (*n* = 20), mucostasis (*n* = 16), and stent migration (*n* = 3), most complications were manageable with additional procedures.

Survival and prognosis {#Sec10}
----------------------

Table [4](#Tab4){ref-type="table"} shows the independent prognostic factors related to mortality based on univariate and multivariate Cox proportional hazard regressions. First, of the host-related factors, chronic pulmonary disease (adjusted hazard ratio \[aHR\], 1.640; 95% confidence interval \[CI\], 1.082--2.488; *P* = 0.020) and poor performance status (aHR, 1.750; 95% CI, 1.206--2.540; *P* = 0.003) were associated with poor survival. Second, of the lesion-related factors, an extended lesion was significantly associated with worse survival compared to a single lesion (aHR, 1.545; 95% CI, 1.035--2.305; *P* = 0.033). In addition, extrinsic compression (aHR, 2.119; 95% CI, 1.120--4.011; *P* = 0.021) and mixed lesions (aHR, 2.388; 95% CI, 1.657--3.442; *P* \<  0.001) had a lower survival rate than endobronchial lesions. Finally, of the disease status and adjuvant treatment-related factors, patients with MCAO as disease progression without adjuvant treatment (aHR, 5.099; 95% CI, 3.075--8.453; *P* \<  0.001) had the worst survival among all the patient groups. Patients who were diagnosed with MCAO during initial diagnosis but did not receive adjuvant treatment (aHR, 2.370; 95% CI, 1.349--4.162; *P* = 0.003) and patients identified as having MCAO during disease progression who did receive adjuvant treatments (aHR, 2.179; 95% CI, 1.413--3.359; *P* \<  0.001) had similar worse prognoses than those diagnosed with MCAO during initial diagnosis who received adjuvant treatments. Table 4Prognostic factors related to mortality (*n* = 224)VariableUnivariable Cox regressionMultivariable Cox regressionUnadjusted HR (95% CI)*P*Adjusted HR (95% CI)*P****Host-related factors*** Age, years1.018 (0.997--1.039)0.090 Sex, male1.192 (0.721--1.969)0.493 Body mass index, kg/m^2^0.936 (0.887--0.987)0.015Smoking history NoReference Yes1.062 (0.709--1.589)0.772Comorbidity Chronic pulmonary disease1.764 (1.135--2.740)0.0121.640 (1.082--2.488)0.020 Diabetes mellitus1.625 (0.989--2.670)0.055 Congestive heart disease0.719 (0.369--1.401)0.332 Chronic liver disease0.458 (0.194--1.082)0.0750.529 (0.231--1.211)0.132 Chronic kidney disease1.723 (0.488--6.081)0.398 Cerebrovascular disease0.616 (0.077--4.913)0.647Poor performance status^a^1.946 (1.276--2.968)0.0021.750 (1.206--2.540)0.003Intubation due to respiratory failure before intervention0.881 (0.500--1.553)0.661Histological type of malignancy AdenocarcinomaReference Squamous cell carcinoma1.075 (0.662--1.746)0.769 Others^b^1.306 (0.614--2.777)0.489 Small cell carcinoma1.863 (0.750--4.627)0.180***Lesion-related factors*** Site of lesion  Single lesionReferenceReference  Extended lesion1.399 (0.903--2.167)0.1331.545 (1.035--2.305)0.033Type of obstruction Endobronchial lesionReferenceReference Extrinsic compression2.525 (1.245--5.125)0.0102.119 (1.120--4.011)0.021 Mixed lesion2.555 (1.685--3.874)\<  0.0012.388 (1.657--3.442)\<  0.001Severity of stenosis (Myer and Cotton grade)^c^ II and IIIReference IV1.272 (0.887--1.824)0.191Length of MCAO^d^, mm1.002 (0.988--1.016)0.787Combined fistula0.487 (0.157--1.511)0.213***Disease status and adjuvant treatment-related factors*** MCAO as initial diagnosis with adjuvant treatmentReferenceReference MCAO as initial diagnosis without adjuvant treatment2.344 (1.318--4.169)0.0042.370 (1.349--4.162)0.003 MCAO as disease progression with adjuvant treatment2.122 (1.352--3.332)0.0012.179 (1.413--3.359)\<  0.001 MCAO as disease progression without adjuvant treatment5.296 (3.142--8.926)\<  0.0015.099 (3.075--8.453)\<  0.001*HR* hazard ratio; *CI* confidential interval; *MCAO* malignant central airway obstruction^a^ American Society of Anesthesiologists (ASA) physical status grade ≥ 3 means severe systemic disease with functional limitation^b^ Poorly differentiated (*n* = 7), large cell neuroendocrine carcinoma (*n* = 3), pleomorphic carcinoma (*n* = 3), lymphoepithelioma-like carcinoma (*n* = 1), sarcomatoid carcinoma (*n* = 1), basaloid squamous cell carcinoma (*n* = 1)^c^ Categorization based on the percentage of reduction in cross-sectional area. Grade 1, ≤ 50% lumenal stenosis; Grade II, 51--70% lumenal stenosis; Grade III, 71--99% luminal stenosis; Grade IV, no lumen^d^ Length of MCAO was defined as the sum of the length of the obstructive lesions more than grade II

The overall survival period had a median of 7.0 months; the one-year and two-year survival rates were 39.7 and 28.3%, respectively (Fig. [1](#Fig1){ref-type="fig"}a). Figure [1](#Fig1){ref-type="fig"} also shows the overall survival after the first bronchoscopic intervention according to independent prognostic factors (existence of chronic pulmonary disease, performance status, site of lesion, type of obstruction, and detection time for MCAO with or without adjuvant treatment). Fig. 1The overall survival rate of patients after interventional bronchoscopy. Survival rates based on (**a**) total participants, (**b**) chronic pulmonary disease, (**c**) poor performance status, (**d**) site of the lesion, (**e**) type of obstruction, and (**f**) detection time of MCAO and possibility of adjuvant treatment after interventional bronchoscopy. MCAO, malignant central airway obstruction

Discussion {#Sec11}
==========

In this study, technical success of interventional bronchoscopy was achieved in 93.7% of patients with MCAO due to primary pulmonary malignancy, and the procedure-related death rate was only 1.3%. An important point of our study is that we tried to identify the independent prognostic factors associated with survival after the first bronchoscopic intervention.

Most patients with primary pulmonary malignancy die from disease progression or complications during treatment, and MCAO is one of the major complications causing death \[[@CR4], [@CR5]\]. Interventional bronchoscopy is gradually being considered a safe procedure and can provide immediate symptomatic relief of dyspnea \[[@CR14], [@CR24]\]. In the long-term, primary pulmonary malignancy patients with MCAO treated by bronchoscopic intervention have similar survival rates to those without MCAO \[[@CR25]\]. Recent studies have confirmed the safety and efficacy of interventional bronchoscopy, and its role as a treatment modality is expected to increase over time \[[@CR14], [@CR26]\]. However, considering the risk of general anesthesia during the procedure, complications, and failure rate around 5%, it is essential to identify the best candidates for interventional bronchoscopy \[[@CR27], [@CR28]\].

We investigated the prognostic factors that affect survival after bronchoscopic intervention. First, of the host-related factors, poor performance status and chronic pulmonary disease were associated with poor survival. Patient general health status was reported by previous studies to be a representative factor \[[@CR13], [@CR27]\]. As patient performance status decreases, procedure-related complications, such as pneumonia and respiratory distress, may increase, and the opportunity for adjuvant treatment after interventional bronchoscopy may decrease \[[@CR14]\]. In addition, smoking status and chronic pulmonary disease were risk factors of complications after bronchoscopic intervention \[[@CR29]\]. Therefore, we think poor performance status and chronic pulmonary disease might be independently associated with survival after the first bronchoscopic intervention.

Second, lesion-related factors are degree of extension and type of obstruction at the lesion. In a previous study, patients with single lesion restricted to one lung demonstrated a better survival than those with tracheal obstruction and involvement of both bronchi \[[@CR30]\]. Our study showed that extensive lesion was one of the prognostic factors for poor survival. In the case of single lesions, airway patency could be maintained by stenting or other treatment modalities until adjuvant treatments became available. However, in the case of extension lesions, it is possible that the MCAO may recur before adjuvant treatment can begin. The frequency of complications may also increase with repeated obstructions. Endobronchial lesions can be treated by mechanical debulking or laser cauterization, but mixed lesions require multimodality therapy to maintain airway patency \[[@CR31]\]. Multimodality therapy often increases the incidence of procedure-related complications and patient mortality \[[@CR27], [@CR28]\]. In patients with extrinsic compression, stent insertion is needed to maintain airway patency, but stent placement was one of the risk factors of post-intervention complications and was correlated with poorer survival \[[@CR27], [@CR32]\]. In this study, a mixed lesion and extrinsic compression were also prognostic factors of poor survival and could be explained using the reasons described above.

Finally, disease status and adjuvant treatment-related factors are detection time of MCAO and possibility of adjuvant treatment. Many studies have addressed the correlation between additional therapy and survival. Adjuvant treatment after bronchoscopic intervention is known to be associated with a better survival rate \[[@CR7], [@CR12], [@CR21]\]. In addition, several studies have explored the impact of previous history of anti-cancer therapy. Jeon et al. demonstrated that newly diagnosed and untreated MCAO patients had a longer survival time following bronchoscopic intervention, and Perin et al. reported that previous chemotherapy was a potential risk factor of intervention-related complications \[[@CR12], [@CR29]\]. In contrast, Guibert et al. showed that patients who had been previously treated for MCAO had a better survival rate \[[@CR13]\]. Despite these results, Guibert et al. recommended that bronchoscopic intervention should be considered as an early multimodal treatment, not a last action. Because they identified a selection bias among previously untreated patients who received fewer additional treatments after intervention. In our study, patients who were initially diagnosed with MCAO and had undergone adjuvant therapy had the best survival rate among all the patient groups. MCAO caused by disease progression with adjuvant therapy had a similar prognosis as initially diagnosed MCAO without adjuvant therapy. These results suggest that possibility of adjuvant therapy and initial diagnosis are important factors related to survival.

Certain limitations of our study must be acknowledged. First, this was a retrospective study with a single-institution design, which is a source of selection bias. Especially, the proportion of chronic pulmonary disease was reported to 20% in this retrospective study, which is far lower than 30--35% of the largest multicenter cohort study for patients with malignant central airway obstruction \[[@CR14]\]. Therefore, the effect of comorbidities may not be properly assessed on the prognosis. Second, treatment options for patients in the terminal stage of primary pulmonary malignancy, such as chemoradiotherapy and supportive care, have advanced over time. These developments might have influenced the slower disease progression and better survival rates of patients in the later study phase compared with those in the earlier study phase. Finally, we were unable to obtain patient spirometric data, quality of life, and symptom scores before and after the bronchoscopic intervention. Most procedures for MCAO patients were provided as palliative therapy, so symptom scores or quality of life assessments might be important factors to consider in this patient population.

Conclusions {#Sec12}
===========

In conclusion, bronchoscopic intervention could be a safe and effective procedure for patients with MCAO due to primary pulmonary malignancy. In addition, a poor survival rate was associated with chronic pulmonary disease, poor performance status, extended lesion (vs. single lesion), mixed lesion or extrinsic compression (vs. endobronchial lesion), and MCAO detected as part of the disease progression and/or not receiving adjuvant treatment after the bronchoscopic intervention. This study will help clinicians to determine the best candidates for bronchoscopic intervention among patients with MCAO due to primary pulmonary malignancy.
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